Zogenix Company Profile (NASDAQ:ZGNX)

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Medical Devices
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ZGNX
  • CUSIP: 98978L10
  • Web: www.zogenix.com
Capitalization:
  • Market Cap: $372.2 million
  • Outstanding Shares: 24,813,000
Average Prices:
  • 50 Day Moving Avg: $13.18
  • 200 Day Moving Avg: $11.30
  • 52 Week Range: $7.33 - $15.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.93
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $22.34 million
  • Price / Sales: 16.66
  • Book Value: $4.07 per share
  • Price / Book: 3.69
Profitability:
  • EBIDTA: ($68,120,000.00)
  • Net Margins: -360.89%
  • Return on Equity: -57.74%
  • Return on Assets: -31.06%
Debt:
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 5.39%
  • Quick Ratio: 4.89%
Misc:
  • Average Volume: 196,331 shs.
  • Beta: 1.95
  • Short Ratio: 33.7
 

Frequently Asked Questions for Zogenix (NASDAQ:ZGNX)

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.85) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.03. The company earned $2.70 million during the quarter, compared to analyst estimates of $4.23 million. Zogenix had a negative return on equity of 57.74% and a negative net margin of 360.89%. Zogenix's quarterly revenue was down 70.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.42) EPS. View Zogenix's Earnings History.

Where is Zogenix's stock going? Where will Zogenix's stock price be in 2017?

3 brokers have issued 12-month price objectives for Zogenix's shares. Their predictions range from $17.00 to $28.00. On average, they anticipate Zogenix's stock price to reach $24.33 in the next year. View Analyst Ratings for Zogenix.

What are analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:

  • 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (3/15/2017)
  • 2. Aegis analysts commented, "adjunctive anti-epileptic therapy."Yang comments, "Study 1504 - a two cohort study to assess ZX008 as an adjunctive antiepileptic therapy. Designed as a multi-center study, 1504 is portioned into two cohorts that are a part of the phase III program for ZX008 in Dravet Syndrome. The first cohort assessed the pharmacokinetics and safety profile of ZX008 (fenfluramine hydrochloride), valproate, and clobazam when administered with stiripentol. In assessing these two aspects, cohort 1 served its primary purpose - identify the appropriate dosage of ZX008 to be used in the second cohort of the trial (0.5 mg/kg/day). Cohort 2 is designed as a double-blind, placebocontrolled trial randomizing 70 patients 1:1 (ZX008:placebo) after a 6 week baseline observation period. After a 3 week titration period, patients will receive either 0.5 mg/kg/day of ZX008 or equivalent placebo before being assessed at 12 weeks. The primary endpoint for cohort 2 is change from baseline in frequency of convulsive seizures, the same as study 1501 and 1502. All patients enrolled in the "stiripentol incomplete responder" trial will remain on their stable stiripentol drug regimen in addition to receiving either ZX008 or placebo." (2/14/2017)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:

  • Cam L. Garner, Independent Chairman of the Board
  • Stephen J. Farr Ph.D., President, Chief Executive Officer, Director
  • Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary
  • Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer
  • Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer
  • Thierry J P Darcis, Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
  • James B. Breitmeyer M.D., Ph.D., Director
  • Roger L. Hawley, Director
  • Erle T. Mast, Independent Director
  • Mark C. Wiggins, Independent Director

Who owns Zogenix stock?

Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (9.88%), Perceptive Advisors LLC (8.88%), FMR LLC (0.00%), Kennedy Capital Management Inc. (0.00%), Vanguard Group Inc. (0.00%) and Goldman Sachs Group Inc. (3.54%). Company insiders that own Zogenix stock include Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Who sold Zogenix stock? Who is selling Zogenix stock?

Zogenix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, City Financial Investment Co Ltd, Bank of America Corp DE, Wells Fargo & Company MN, Morgan Stanley, JPMorgan Chase & Co., TIAA CREF Investment Management LLC and ProShare Advisors LLC. View Insider Buying and Selling for Zogenix.

Who bought Zogenix stock? Who is buying Zogenix stock?

Zogenix's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Kennedy Capital Management Inc., Dimensional Fund Advisors LP, Sphera Funds Management LTD., Candriam Luxembourg S.C.A., Vanguard Group Inc., Ameriprise Financial Inc. and California Public Employees Retirement System. Company insiders that have bought Zogenix stock in the last two years include Renee P Tannenbaum and Roger Hawley. View Insider Buying and Selling for Zogenix.

How do I buy Zogenix stock?

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of Zogenix stock can currently be purchased for approximately $15.00.


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zogenix (NASDAQ:ZGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.33 (62.22% upside)

Analysts' Ratings History for Zogenix (NASDAQ:ZGNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
10/4/2016Leerink SwannReiterated RatingOutperform$17.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
11/10/2015William BlairInitiated CoverageHoldN/AView Rating Details
10/21/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$23.00N/AView Rating Details
(Data available from 6/24/2015 forward)

Earnings

Earnings History for Zogenix (NASDAQ:ZGNX)
Earnings by Quarter for Zogenix (NASDAQ:ZGNX)
Earnings History by Quarter for Zogenix (NASDAQ ZGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zogenix (NASDAQ:ZGNX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.85)($0.85)($0.85)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zogenix (NASDAQ:ZGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zogenix (NASDAQ:ZGNX)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 87.10%
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.00View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.00View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.00View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zogenix (NASDAQ:ZGNX)
Latest Headlines for Zogenix (NASDAQ:ZGNX)
Source:
DateHeadline
streetinsider.com logoZogenix (ZGNX) Announces Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome - StreetInsider.com
www.streetinsider.com - June 23 at 12:57 AM
streetinsider.com logoZogenix (ZGNX) Announces Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
www.streetinsider.com - June 22 at 2:55 PM
finance.yahoo.com logoZogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
finance.yahoo.com - June 22 at 2:55 PM
americanbankingnews.com logoReviewing Nuvectra Corporation (NVTR) and Zogenix (ZGNX)
www.americanbankingnews.com - June 21 at 12:22 AM
americanbankingnews.com logoKythera Biopharmaceuticals (KYTH) and Zogenix (ZGNX) Head to Head Review
www.americanbankingnews.com - June 11 at 8:22 PM
americanbankingnews.com logoZogenix Sees Unusually Large Options Volume (ZGNX)
www.americanbankingnews.com - June 11 at 7:06 AM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : June 8, 2017
finance.yahoo.com - June 9 at 3:03 AM
americanbankingnews.com logo Brokerages Anticipate Zogenix, Inc. (ZGNX) Will Post Quarterly Sales of $4.63 Million
www.americanbankingnews.com - June 8 at 1:32 PM
americanbankingnews.com logo-$0.91 Earnings Per Share Expected for Zogenix, Inc. (ZGNX) This Quarter
www.americanbankingnews.com - June 6 at 7:18 AM
seekingalpha.com logoBiotech Forum Daily Digest: Will Tesaro Get Bids? Spotlight On Zogenix
seekingalpha.com - June 3 at 2:54 AM
finance.yahoo.com logoZogenix to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 31 at 11:27 AM
finance.yahoo.com logoZogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
finance.yahoo.com - May 22 at 7:48 PM
seekingalpha.com logoZogenix: Buy The Run-Up Into Third Quarter Data - Seeking Alpha
seekingalpha.com - May 16 at 8:02 AM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:26 PM
americanbankingnews.com logoZacks: Analysts Anticipate Zogenix, Inc. (ZGNX) Will Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - May 10 at 2:08 PM
finance.yahoo.com logoZogenix, Inc. :ZGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 8:50 PM
seekingalpha.com logoZogenix's (ZGNX) CEO Stephen Farr on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 2:20 AM
finance.yahoo.com logoInvestor Network: Zogenix, Inc. to Host Earnings Call
finance.yahoo.com - May 6 at 2:20 AM
finance.yahoo.com logoZogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 6 at 2:20 AM
finance.yahoo.com logoEdited Transcript of ZGNX earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 6 at 2:20 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 5 at 2:04 PM
marketbeat.com logoZogenix reports 1Q loss
marketbeat.com - May 4 at 6:34 PM
americanbankingnews.com logoZogenix (ZGNX) Receiving Somewhat Negative Press Coverage, Analysis Shows
www.americanbankingnews.com - May 2 at 10:38 AM
finance.yahoo.com logoBlog Coverage Zogenix Announces Completion of Enrollment for the Phase III Trial in Dravet Syndrome
finance.yahoo.com - May 1 at 9:45 AM
seekingalpha.com logoZogenix, Inc. (ZGNX)
seekingalpha.com - April 29 at 2:56 AM
seekingalpha.com logoLast patient randomized in Zogenix's late-stage study of ZX008 in Dravet
seekingalpha.com - April 28 at 8:04 AM
finance.yahoo.com logoZogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
finance.yahoo.com - April 27 at 11:20 AM
finance.yahoo.com logoZogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
finance.yahoo.com - April 27 at 11:20 AM
americanbankingnews.com logoZogenix (ZGNX) Getting Somewhat Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 8:29 AM
americanbankingnews.com logo$5.23 Million in Sales Expected for Zogenix, Inc. (ZGNX) This Quarter
www.americanbankingnews.com - April 27 at 1:07 AM
americanbankingnews.com logoZacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Announce Earnings of -$0.88 Per Share
www.americanbankingnews.com - April 27 at 1:06 AM
americanbankingnews.com logoZogenix (ZGNX) Given News Sentiment Score of 0.69
www.americanbankingnews.com - April 22 at 7:47 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Expected to Post Quarterly Sales of $5.23 Million
www.americanbankingnews.com - April 21 at 2:07 PM
americanbankingnews.com logoZacks: Analysts Expect Zogenix, Inc. (ZGNX) to Post -$0.88 Earnings Per Share
www.americanbankingnews.com - April 19 at 6:21 PM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 7:32 PM
americanbankingnews.com logoZogenix (ZGNX) Receiving Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 13 at 9:20 AM
finance.yahoo.com logoETFs with exposure to Zogenix, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 1:40 PM
americanbankingnews.com logoShort Interest in Zogenix, Inc. (ZGNX) Expands By 1.3%
www.americanbankingnews.com - April 5 at 8:16 AM
americanbankingnews.com logoRenee P. Tannenbaum Purchases 5,000 Shares of Zogenix, Inc. (ZGNX) Stock
www.americanbankingnews.com - March 20 at 8:13 PM
finance.yahoo.com logoZogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 16 at 8:52 AM
finance.yahoo.com logoZOGENIX, INC. Financials
finance.yahoo.com - March 16 at 8:52 AM
americanbankingnews.com logoZogenix, Inc. (ZGNX) Given “Buy” Rating at Aegis
www.americanbankingnews.com - March 11 at 8:52 PM
americanbankingnews.com logoZogenix’s (ZGNX) “Buy” Rating Reaffirmed at Aegis
www.americanbankingnews.com - March 11 at 8:52 PM
biz.yahoo.com logoQ4 2016 Zogenix Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 11 at 11:29 AM
us.rd.yahoo.com logoZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
us.rd.yahoo.com - March 11 at 11:29 AM
us.rd.yahoo.com logo4:04 pm Zogenix misses by $0.08, beats on revs
us.rd.yahoo.com - March 11 at 11:29 AM
biz.yahoo.com logoZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 11 at 11:29 AM
biz.yahoo.com logoZOGENIX, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 11 at 11:29 AM
seekingalpha.com logoZogenix top line up 81%; net loss widens; going concern risk weighs on shares, down 7%
seekingalpha.com - March 10 at 9:22 AM
seekingalpha.com logoZogenix Is On The Precipice Of Substantial Growth - Part 2
seekingalpha.com - March 9 at 6:30 AM

Social

Chart

Zogenix (ZGNX) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by MarketBeat.com Staff